| Cassandra Kridelbaugh, LCSW | |
|
250 W 100 S, Gunnison, UT 84634-8463 | |
| (801) 898-7917 | |
| Not Available |
| Full Name | Cassandra Kridelbaugh |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 250 W 100 S, Gunnison, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124787809 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 7133296-3501 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cassandra Kridelbaugh, LCSW Po Box 220122, Centerfield, UT 84622-0122 Ph: (801) 898-7917 | Cassandra Kridelbaugh, LCSW 250 W 100 S, Gunnison, UT 84634-8463 Ph: (801) 898-7917 |
News Archive
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
In a quest to make safer and more effective vaccines, scientists at the Biodesign Institute- at Arizona State University have turned to a promising field called DNA nanotechnology to make an entirely new class of synthetic vaccines.
Thermal Tennis, Inc., a Nevada corporation that focuses on the development of tennis management and training programs announced today that it has entered into an agreement and plan of merger (the "Merger Agreement") with CannaSys, Inc., a Colorado corporation that provides innovative marketing solutions for the growing medical and recreational cannabis industry.
Researchers from the University of Copenhagen have developed an algorithm that can identify patients who may have been wrongly diagnosed.
At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.
› Verified 8 days ago
Ryan Thomas-eddins Olsen, Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 65 E 100 N, Gunnison, UT 84634 Phone: 435-528-2222 |